COMPANY PROFILE

Neurotrack

Building the cognitive health platform of the future, giving people direct access to tools and technology to assess, strengthen, and monitor their cognitive health

Redwood City, United StatesFounded 2012Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Neurotrack

Neurotrack is a pioneering company in the cognitive health sector, offering a comprehensive program designed to help individuals manage and improve their brain health. The company operates primarily through a mobile app that provides users with clinically validated assessments and eye tracking technology to evaluate their current cognitive abilities. Neurotrack's target clients include individuals concerned about cognitive decline, healthcare providers, and organizations looking to incorporate cognitive health programs for their employees.

Read full description

The market Neurotrack operates in is the digital health and wellness sector, with a specific focus on cognitive health and preventative care. The business model revolves around a subscription-based service, where users pay for access to the app and its suite of tools and assessments. Revenue is generated through individual subscriptions, corporate partnerships, and potentially through collaborations with healthcare providers.

Neurotrack's unique selling proposition lies in its evidence-based approach, leveraging the expertise of neuroscientists, neuropsychologists, and data scientists to deliver actionable insights and preventative strategies. The app not only assesses cognitive health but also provides personalized recommendations for behaviors that can strengthen cognition, such as quality sleep and brain training exercises.

By focusing on early intervention and continuous monitoring, Neurotrack aims to reduce the risk of cognitive decline and empower individuals to take control of their brain health.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Redwood City, United States
Employees: 46
Open positions: None listed
Dealroom signal: 88.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Degenerative Diseases, Health Diagnostics, Spinout, Insurtech Related, Biotech and Pharma, Hard Tech
Technology: Mobile app
Business model: SaaS
Client focus: b2b, b2c
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Nov 2022	$10M	$105M	Undisclosed	↗
SERIES COther financing	Jun 2019	$21M	$84M	AME Cloud Ventures · Rethink Venture Capital · Sompo Holdings · Khosla Ventures	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Neurotrack website traffic

Latest recorded traffic for Neurotrack is 20K monthly website visits, up 122.2% over the last three months. Neurotrack's team grew 17.9% over the past year.

Latest monthly visits20K 3-month web change+122.2% 1-year team growth+17.9%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
ABAnnexon BiosciencesBiotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders	San Francisco, United States	Operational
SDSuperfluid DiagnosticsMolecular Stethoscope, Inc, a San Diego, CA-based biotechnology company developing novel blood-based early detection	San Diego, United States	Operational
EPEpilogProvides advanced EEG analysis for treatment development, diagnostics and monitoring of patients with epilepsy and other CNS diseases	Ghent, Belgium	Operational
APAvraham PharmaceuticalsA pharmaceutical company that develops novel products for the treatment and prevention of neurodegenerative disorders	Rehovot, Israel	Operational
ANAleva NeurotherapeuticsPioneered directional deep brain stimulation DBS in Neuromodulation treatment of Parkinson's disease and essential tremor	Lausanne, Switzerland	Operational
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational